<document id="DDI-DrugBank.d210">
    <sentence id="DDI-DrugBank.d210.s2" text="This interaction should be given consideration in patients taking VIOXX concomitantly with ACE inhibitors.">
        <entity charOffset="66-70" id="DDI-DrugBank.d210.s2.e0" text="VIOXX" type="brand" />
        <entity charOffset="91-104" id="DDI-DrugBank.d210.s2.e1" text="ACE inhibitors" type="group" />
        <pair ddi="true" e1="DDI-DrugBank.d210.s2.e0" e2="DDI-DrugBank.d210.s2.e1" id="DDI-DrugBank.d210.s2.p0" type="advise" />
    </sentence>
    <sentence id="DDI-DrugBank.d210.s5" text="Patients taking low-dose aspirin plus ibuprofen were not studied.">
        <entity charOffset="25-31" id="DDI-DrugBank.d210.s5.e0" text="aspirin" type="brand" />
        <entity charOffset="38-46" id="DDI-DrugBank.d210.s5.e1" text="ibuprofen" type="drug" />
        <pair ddi="false" e1="DDI-DrugBank.d210.s5.e0" e2="DDI-DrugBank.d210.s5.e1" id="DDI-DrugBank.d210.s5.p0" />
    </sentence>
    <sentence id="DDI-DrugBank.d210.s6" text="At steady state, VIOXX 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) aspirin, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.">
        <entity charOffset="17-21" id="DDI-DrugBank.d210.s6.e0" text="VIOXX" type="brand" />
        <entity charOffset="115-121" id="DDI-DrugBank.d210.s6.e1" text="aspirin" type="brand" />
        <pair ddi="false" e1="DDI-DrugBank.d210.s6.e0" e2="DDI-DrugBank.d210.s6.e1" id="DDI-DrugBank.d210.s6.p0" />
    </sentence>
    <sentence id="DDI-DrugBank.d210.s7" text="Because of its lack of platelet effects, VIOXX is not a substitute for aspirin for cardiovascular prophylaxis.">
        <entity charOffset="41-45" id="DDI-DrugBank.d210.s7.e0" text="VIOXX" type="brand" />
        <entity charOffset="71-77" id="DDI-DrugBank.d210.s7.e1" text="aspirin" type="brand" />
        <pair ddi="false" e1="DDI-DrugBank.d210.s7.e0" e2="DDI-DrugBank.d210.s7.e1" id="DDI-DrugBank.d210.s7.p0" />
    </sentence>
    <sentence id="DDI-DrugBank.d210.s9" text="Prospective, long-term studies on concomitant administration of VIOXX and aspirin have not been conducted.">
        <entity charOffset="64-68" id="DDI-DrugBank.d210.s9.e0" text="VIOXX" type="brand" />
        <entity charOffset="74-80" id="DDI-DrugBank.d210.s9.e1" text="aspirin" type="brand" />
        <pair ddi="false" e1="DDI-DrugBank.d210.s9.e0" e2="DDI-DrugBank.d210.s9.e1" id="DDI-DrugBank.d210.s9.p0" />
    </sentence>
    <sentence id="DDI-DrugBank.d210.s20" text="At higher than recommended doses, VIOXX 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving methotrexate 7.5 to 15 mg/week for rheumatoid arthritis.">
        <entity charOffset="34-38" id="DDI-DrugBank.d210.s20.e0" text="VIOXX" type="brand" />
        <entity charOffset="168-179" id="DDI-DrugBank.d210.s20.e1" text="methotrexate" type="drug" />
        <pair ddi="true" e1="DDI-DrugBank.d210.s20.e0" e2="DDI-DrugBank.d210.s20.e1" id="DDI-DrugBank.d210.s20.p0" type="mechanism" />
    </sentence>
    <sentence id="DDI-DrugBank.d210.s26" text="Therefore, a starting daily dose of 25 mg of VIOXX should be considered for the treatment of osteoarthritis when VIOXX is co-administered with potent inducers of hepatic metabolism.">
        <entity charOffset="45-49" id="DDI-DrugBank.d210.s26.e0" text="VIOXX" type="brand" />
        <entity charOffset="113-117" id="DDI-DrugBank.d210.s26.e1" text="VIOXX" type="brand" />
        <pair ddi="false" e1="DDI-DrugBank.d210.s26.e0" e2="DDI-DrugBank.d210.s26.e1" id="DDI-DrugBank.d210.s26.p0" />
    </sentence>
    <sentence id="DDI-DrugBank.d210.s32" text="In single and multiple dose studies in healthy subjects receiving both warfarin and rofecoxib, prothrombin time (measured as INR) was increased by approximately 8% to 11%.">
        <entity charOffset="71-78" id="DDI-DrugBank.d210.s32.e0" text="warfarin" type="drug" />
        <entity charOffset="84-92" id="DDI-DrugBank.d210.s32.e1" text="rofecoxib" type="drug" />
        <pair ddi="true" e1="DDI-DrugBank.d210.s32.e0" e2="DDI-DrugBank.d210.s32.e1" id="DDI-DrugBank.d210.s32.p0" type="effect" />
    </sentence>
    <sentence id="DDI-DrugBank.d210.s33" text="In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving VIOXX concurrently with warfarin.">
        <entity charOffset="168-172" id="DDI-DrugBank.d210.s33.e0" text="VIOXX" type="brand" />
        <entity charOffset="192-199" id="DDI-DrugBank.d210.s33.e1" text="warfarin" type="drug" />
        <pair ddi="true" e1="DDI-DrugBank.d210.s33.e0" e2="DDI-DrugBank.d210.s33.e1" id="DDI-DrugBank.d210.s33.p0" type="effect" />
    </sentence>
</document>